×
Catalent Inventory 2012-2024 | CTLT
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Catalent inventory for the quarter ending June 30, 2024 was
$0.574B
, a
26.13% decline
year-over-year.
Catalent inventory for 2024 was
$0.574B
, a
26.13% decline
from 2023.
Catalent inventory for 2023 was
$0.777B
, a
10.68% increase
from 2022.
Catalent inventory for 2022 was
$0.702B
, a
24.69% increase
from 2021.
View More
Catalent Inventory 2012-2024 | CTLT
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Catalent inventory for 2024 was
$0.574B
, a
26.13% decline
from 2023.
Catalent inventory for 2023 was
$0.777B
, a
10.68% increase
from 2022.
Catalent inventory for 2022 was
$0.702B
, a
24.69% increase
from 2021.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$79.8B
Takeda Pharmaceutical (TAK)
$43.8B
Merck (MKKGY)
$21B
Astellas Pharma (ALPMY)
$20.2B
Sandoz Group AG (SDZNY)
$19.8B
United Therapeutics (UTHR)
$18.3B
Summit Therapeutics (SMMT)
$15.8B
Neurocrine Biosciences (NBIX)
$12.7B
Shionogi (SGIOY)
$12.5B
Madrigal Pharmaceuticals (MDGL)
$7.6B
Jazz Pharmaceuticals (JAZZ)
$7.6B
Orion OYJ (ORINY)
$6.8B
Corcept Therapeutics (CORT)
$6.2B
Ionis Pharmaceuticals (IONS)
$6.2B
Crinetics Pharmaceuticals (CRNX)
$4.9B
PTC Therapeutics (PTCT)
$3.4B
Dyne Therapeutics (DYN)
$2.9B
Catalyst Pharmaceuticals (CPRX)
$2.9B
Arrowhead Pharmaceuticals (ARWR)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Soleno Therapeutics (SLNO)
$2.5B
NewAmsterdam Pharma (NAMS)
$2.2B
Recursion Pharmaceuticals (RXRX)
$2B
Centessa Pharmaceuticals (CNTA)
$1.9B
Harrow (HROW)
$1.9B
Ocular Therapeutix (OCUL)
$1.7B
Xencor (XNCR)
$1.7B
ARS Pharmaceuticals (SPRY)
$1.7B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Avadel Pharmaceuticals (AVDL)
$1.5B